Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Large Drop in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDTGet Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 89,800 shares, a decline of 5.5% from the November 15th total of 95,000 shares. Based on an average daily volume of 361,500 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of Helius Medical Technologies in a report on Wednesday, October 16th.

View Our Latest Stock Report on HSDT

Institutional Trading of Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC bought a new stake in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDTFree Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies at the end of the most recent reporting period. Institutional investors and hedge funds own 18.63% of the company’s stock.

Helius Medical Technologies Stock Down 2.1 %

NASDAQ:HSDT opened at $0.48 on Tuesday. Helius Medical Technologies has a 52 week low of $0.37 and a 52 week high of $9.50. The stock’s 50-day moving average price is $0.52 and its 200-day moving average price is $0.74. The stock has a market capitalization of $1.79 million, a PE ratio of -0.08 and a beta of 1.68.

Helius Medical Technologies Company Profile

(Get Free Report)

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.

See Also

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.